PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Publication date: May 20, 2019

the investigators launched this exploratory study to evaluate the objective response rate (ORR) of SHR-1210 combined with apatinib mesylate in the first-line treatment of patients with advanced acral melanoma.

Concepts Keywords
Arrhythmia Chemotherapy
Autoimmune Radiation
Basal Radiation therapy
Beijing Targeted therapy
Breast Feeding Chemotherapy
Carcinoma Acral lentiginous melanoma
Cervical Carcinoma RTT
Chemotherapy Cancer
Congestive Heart Failure Antineoplastic drugs
Fever Health
Heart Disease Melanoma
Histopathologically Clinical medicine
Hypersensitivity Medicine
Immunotherapy Immunotherapy
Infection Chemotherapy
Informed Consent Radiation therapy
Macromolecular Myocardial infarction
Malignant Unstable angina
Melanoma Systematic anti tumor
Mesylate
Metastatic
Myocardial Infarction
Organ
Physician
Principal Investigator
Radiation Therapy
Resection
Targeted Therapy
Tumor
Unstable Angina
Vaccine
Ventricular Arrhythmia

Semantics

Type Source Name
disease DOID Cancer
disease MESH infection
disease MESH arrhythmia
gene UNIPROT EHD1
disease DOID myocardial infarction
disease MESH myocardial infarction
disease DOID unstable angina
disease MESH unstable angina
disease DOID congestive heart failure
disease MESH congestive heart failure
disease DOID heart disease
disease MESH heart disease
disease DOID autoimmune disease
disease MESH autoimmune disease
disease MESH carcinoma in situ
pathway BSID Basal cell carcinoma
disease DOID basal cell carcinoma
disease MESH basal cell carcinoma
disease DOID hypersensitivity
disease MESH hypersensitivity
disease MESH tumor
disease MESH recurrence
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma
gene UNIPROT PDCD1
gene UNIPROT RPL17

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *